These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 10672837)

  • 1. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid.
    Berstad A; Arslan G; Folvik G
    Scand J Gastroenterol; 2000 Jan; 35(1):64-9. PubMed ID: 10672837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease.
    Bunn SK; Bisset WM; Main MJ; Golden BE
    J Pediatr Gastroenterol Nutr; 2001 Feb; 32(2):171-7. PubMed ID: 11321388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with subjective food hypersensitivity: the value of analyzing intestinal permeability and inflammation markers in gut lavage fluid.
    Arslan G; Kahrs GE; Lind R; Frøyland L; Florvaag E; Berstad A
    Digestion; 2004; 70(1):26-35. PubMed ID: 15297775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease.
    Røseth AG; Schmidt PN; Fagerhol MK
    Scand J Gastroenterol; 1999 Jan; 34(1):50-4. PubMed ID: 10048733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.
    Tibble JA; Sigthorsson G; Bridger S; Fagerhol MK; Bjarnason I
    Gastroenterology; 2000 Jul; 119(1):15-22. PubMed ID: 10889150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of ileal pouch inflammation by single-stool calprotectin assay.
    Thomas P; Rihani H; Røseth A; Sigthorsson G; Price A; Nicholls RJ; Bjarnason I
    Dis Colon Rectum; 2000 Feb; 43(2):214-20. PubMed ID: 10696896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of calprotectin level in gingival crevicular fluid with gingival index and the activities of collagenase and aspartate aminotransferase in adult periodontitis patients.
    Nakamura T; Kido J; Kido R; Ohishi K; Yamauchi N; Kataoka M; Nagata T
    J Periodontol; 2000 Mar; 71(3):361-7. PubMed ID: 10776922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is fecal calprotectin the next standard in inflammatory bowel disease activity tests?
    Alic M
    Am J Gastroenterol; 1999 Nov; 94(11):3370-1. PubMed ID: 10566749
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure.
    Kristensen V; Malmstrøm GH; Skar V; Røseth A; Moum B
    Scand J Gastroenterol; 2016; 51(5):548-55. PubMed ID: 26634305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is moderate red wine consumption safe in inactive inflammatory bowel disease?
    Swanson GR; Tieu V; Shaikh M; Forsyth C; Keshavarzian A
    Digestion; 2011; 84(3):238-44. PubMed ID: 21876358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children.
    Olafsdottir E; Aksnes L; Fluge G; Berstad A
    Acta Paediatr; 2002; 91(1):45-50. PubMed ID: 11883817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory bowel disease is associated with increased gut-to-blood penetration of short-chain fatty acids: A new, non-invasive marker of a functional intestinal lesion.
    Jaworska K; Konop M; Bielinska K; Hutsch T; Dziekiewicz M; Banaszkiewicz A; Ufnal M
    Exp Physiol; 2019 Aug; 104(8):1226-1236. PubMed ID: 31243807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease.
    Tibble JA; Sigthorsson G; Foster R; Forgacs I; Bjarnason I
    Gastroenterology; 2002 Aug; 123(2):450-60. PubMed ID: 12145798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics.
    Kristinsson J; Armbruster CH; Ugstad M; Kriwanek S; Nygaard K; Tøn H; Fuglerud P
    Scand J Gastroenterol; 2001 Feb; 36(2):202-7. PubMed ID: 11252414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing intestinal permeability in Crohn's disease patients using orally administered 52Cr-EDTA.
    von Martels JZH; Bourgonje AR; Harmsen HJM; Faber KN; Dijkstra G
    PLoS One; 2019; 14(2):e0211973. PubMed ID: 30730969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
    Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
    Aliment Pharmacol Ther; 2016 May; 43(10):1069-79. PubMed ID: 26953251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
    Sydora MJ; Sydora BC; Fedorak RN
    J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of NSAID enteropathy as shown by a simple faecal test.
    Tibble JA; Sigthorsson G; Foster R; Scott D; Fagerhol MK; Roseth A; Bjarnason I
    Gut; 1999 Sep; 45(3):362-6. PubMed ID: 10446103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.